European urology最新文献

{"title":"Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review","authors":"Nora Sundahl, Laurence Albiges, Toni K. Choueiri, Elise De Bleser, Gert De Meerleer, Raquibul Hannan, Rana McKay, Chad Tang, Shankar Siva","doi":"10.1016/j.eururo.2025.03.016","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.016","url":null,"abstract":"<h3>Background and objective</h3>Despite its radioresistant reputation, renal cell carcinoma (RCC) is sensitive to high dose per fraction stereotactic ablative body radiotherapy (SABR). As SABR also triggers immunomodulatory effects, a combination of SABR and immunotherapy for RCC might improve patient outcomes. The current systematic review will discuss all prospective studies on SABR alone or combined with immunotherapy.<h3>Methods</h3>A systematic review was conducted in January 2025 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement on the PubMed and Cochrane databases. Thirty-eight studies were included in this review.<h3>Key findings and limitations</h3>In the primary setting, 15 prospective studies have proved SABR to be a valuable alternative for (partial) nephrectomy for high-risk or medically inoperable patients, with good tolerability and excellent local control. No prospective studies have reported on SABR combined with immunotherapy in nonmetastatic patients. In the oligometastatic setting, two phase 2 trials have investigated SABR in lieu of systemic treatment. This showed encouraging results, with the majority of patients being free from systemic therapy at 1 yr. SABR combined with immunotherapy in the metastatic setting has been investigated in multiple phase 1 and 2 trials, where the most promising option seems to be SABR to multiple—preferentially all—lesions. Cytoreductive SABR and SABR to oligoprogressive lesions combined with immunotherapy are attractive future strategies.<h3>Conclusions and clinical implications</h3>SABR is a valid alternative in localised RCC when (partial) nephrectomy is not an option. In the metastatic setting, several early-phase trials have investigated SABR alone and in combination with immunotherapy, warranting future large, randomised trials.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"183 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143820034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Salvage Robotic-assisted Radical Prostatectomy: High-volume Multicentric Data from the European Association of Urology Robotic Urology Section Scientific Working Group","authors":"Marcio Covas Moschovas, Shady Saikali, Marco Sandri, Carlo Bravi, Ugo Falagario, Arjun Nathan, Justin Collins, Eleonora Balestrazzi, Gert de Naeyer, Ruben Groote, Maria Chiara Sighinolfi, Sophie Knipper, Markus Graefen, Randi Pose, Guillaume Ploussard, Hamza Idais, Hubert John, Angelo Mottaran, Riccardo Schiavina, Pietro Piazza, Peter Wiklund","doi":"10.1016/j.eururo.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.009","url":null,"abstract":"<h3>Background and objective</h3>Salvage robotic-assisted radical prostatectomy (S-RARP) is one option for treating patients with recurrent prostate cancer after prostate-preserving primary therapy. However, the tissue damage, anatomical distortion, and lack of surgical landmarks caused by the primary treatment still constitute a major challenge to surgeons. We aim to report the experience of our group on S-RARP.<h3>Methods and surgical procedure</h3>A retrospective multicentric study including data from nine centers from the European Association of Urology Robotic Urology Section Scientific Working Group was conducted. Overall, 397 patients who underwent S-RARP from 2008 to 2023 were included and divided into three groups (primary radiation therapy [RT], whole gland [WG] ablation, and focal gland [FG] ablation). The primary endpoints were the safety and feasibility of S-RARP. The secondary endpoints were the comparison of functional and oncological outcomes among different primary therapies.<h3>Key findings and limitations</h3>The median (interquartile range) follow-up periods for RT, FG ablation, and WG ablation were 38 (19–73), 20 (10–37), and 24 (16–38) mo, respectively (<em>p</em> &lt; 0.001). Only four patients (1%) had intraoperative complications and &lt;2% had Clavien grade ≥3 after surgery. The 5-yr cumulative incidence rates of biochemical recurrence were 35%, 45%, and 23% for RT, FG ablation, and WG ablation, respectively (<em>p</em> = 0.3). The 3-yr cumulative incidence rates of continence were 67%, 92%, and 71% for RT, FG ablation, and WG ablation, respectively (<em>p</em> &lt; 0.001). The 5-yr cumulative incidence rates of potency were 16%, 11%, and 5.3% (<em>p</em> = 0.2), while the overall survival rates at 5 yr were 95%, 94%, and 100% for RT, FG ablation, and WG ablation, respectively (<em>p</em> = 0.7).<h3>Conclusions</h3>S-RARP is safe and feasible with very low rates of perioperative complications. Functional outcomes in patients undergoing S-RARP are inferior to outcomes at primary surgery and demand highly skilled surgical expertise. Patients should be counseled carefully that the functional outcomes are inferior to those at primary surgery.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"108 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: HIF Regulates Multiple Translated Endogenous Retroviruses: Implications for Cancer Immunotherapy","authors":"Aimin Jiang, Ying Liu, Peng Luo, Anqi Lin, Linhui Wang, Hanzhong Zhang","doi":"10.1016/j.eururo.2025.03.014","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.014","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"53 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.12.015","authors":"Christopher Sweeney, Meng He, Matthew Wongchenko, Roberta Ferraldeschi, Johann S. de Bono","doi":"10.1016/j.eururo.2025.03.020","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.020","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"21 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: A Reference Standard for Urinary Tract Infection Research: A Multidisciplinary Delphi Consensus Study","authors":"Maxime Vallée","doi":"10.1016/j.eururo.2025.03.021","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.021","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"39 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Male-partner Treatment to Prevent Recurrence of Bacterial Vaginosis","authors":"Alejandra Vásquez Hernández, Jenniffer Puerta-Suárez, Walter D. Cardona Maya","doi":"10.1016/j.eururo.2025.03.015","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.015","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"75 1 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143814114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Brian Shuch, Allan J. Pantuck, Jean-Christophe Bernhard, et al. [89Zr]Zr-girentuximab for PET-CT Imaging of Clear-cell Renal Cell Carcinoma: A Prospective, Open-label, Multicentre, Phase 3 Trial. Lancet Oncol 2024;25:1277–87","authors":"Zhuo Tony Su, Mohammad E. Allaf, Nirmish Singla","doi":"10.1016/j.eururo.2025.01.025","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.01.025","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"65 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Ventral Versus Dorsal Onlay Buccal Mucosal Graft Urethroplasty for Non-traumatic Proximal Bulbar Urethral Strictures in Sexually Active Men: Erectile and Urinary Functions","authors":"Navid Roessler, Jakob Klemm, Wesley Verla, Malte W. Vetterlein","doi":"10.1016/j.eururo.2025.03.013","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.013","url":null,"abstract":"No Abstract","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143805955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen–targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer","authors":"Silu Chen, Hongchuang Xu, Xueqi Chen, Qi Shen, Xu Chen, Meng Zhang, Zhihua Li, Zhongyuan Zhang, Han Hao, Wei Yu, Yan Fan, Liqun Zhou, Ning Zhang, Jianhua Zhang, Xing Yang, Cheng Shen, Xuesong Li","doi":"10.1016/j.eururo.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.010","url":null,"abstract":"<h3>Background and objective</h3>Accurately distinguishing between cancerous and noncancerous tissues during robot-assisted radical prostatectomy (RARP) is a challenge that can increase the risk of residual disease. This study aimed to evaluate the safety, optimal dose and accuracy of a dual-modality prostate-specific membrane antigen (PSMA)-targeted probe (⁶⁸Ga-P3) for preoperative positron emission tomography (PET)/computed tomography (CT) imaging and intraoperative fluorescence imaging in prostate cancer.<h3>Methods and surgical procedure</h3>Each participant received an intravenous chemical dose of ⁶⁸Ga-P3 (10, 20, and 40 μg/kg), with radioactivity of 3.7 MBq/kg. PET/CT imaging was conducted 30, 60, and 120 min after injection to evaluate its biodistribution and dosimetry. RARP was performed at 24 ± 6 h after injection, in the sensitive mode of Firefly fluorescence imaging.<h3>Key findings and limitations</h3>Between May 2024 and July 2024, a total of 16 patients were included; ⁶⁸Ga-P3 was well tolerated without any adverse events related to ⁶⁸Ga-P3 administration or fluorescence imaging. At 2 h after administration, the median tumor maximum standardized uptake value was 5.3 (4.1–8.1). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ⁶⁸Ga-P3 PET/CT for tumor localization were 79.1%, 90.4%, 81.5%, and 89.0%, respectively. The overall NPV, PPV, and accuracy of intraoperative fluorescence imaging were 100%, 43.8%, and 90.9%, respectively. Of overall false-positive sites, 88.9% (8/9) were confirmed as tumor adjacent to the surgical margin. A dose of 40 μg/kg resulted in the highest accuracy of 92.3%.<h3>Conclusions and clinical implications</h3>In PSMA-targeted PET imaging and fluorescence-guided surgery, ⁶⁸Ga-P3 is safe and feasible for use, offering a novel tool for the surgical management of prostate cancer.","PeriodicalId":12223,"journal":{"name":"European urology","volume":"25 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143806001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]","authors":"Andrew J. Armstrong, Oliver Sartor, Johann de Bono, Kim Chi, Karim Fizazi, Bernd J. Krause, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Fred Saad, Tomasz M. Beer, Jiwen Wu, Osvaldo Mirante, Michael J. Morris","doi":"10.1016/j.eururo.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.eururo.2025.03.008","url":null,"abstract":"The authors regret a minor data error in the reporting of best radiographic responses in Supplementary Table 5 in the Supplementary Material. The percentage of patients with an evaluable response who had progressive disease (PD) in the 'Increase' subgroup for best overall PSA decline from baseline in the ¹⁷⁷Lu-PSMA-617 arm should be 31% not 40%. The number of patients with PD (<em>n</em> = 22) and the denominator (<em>n</em> = 71) remain correct. The data in the Table should therefore read as ‘22 (31)’ not ‘22 (40)’. The authors also note that the rows in this Table are slightly misaligned vertically but are presented in the correct order.<span><figure><span><img alt=\"\" height=\"479\" src=\"https://ars.els-cdn.com/content/image/1-s2.0-S0302283825001794-fx1.jpg\"/><ol><li><span><span>Download: <span>Download high-res image (521KB)</span></span></span></li><li><span><span>Download: <span>Download full-size image</span></span></span></li></ol></span></figure></span>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"217 1","pages":""},"PeriodicalIF":23.4,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143798181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}